Welcome to the UPF Digital Repository

Drug-related problems in patients admitted for SARS-CoV-2 infection during the COVID-19 pandemic

Show simple item record

dc.contributor.author Barceló-Vidal, Jaime
dc.contributor.author Echeverría Esnal, Daniel
dc.contributor.author Carballo Martínez, Núria
dc.contributor.author De Antonio Cuscó, Marta
dc.contributor.author Fernández-Sala, Xènia
dc.contributor.author Navarrete Rouco, Maria Eugenia
dc.contributor.author Colominas-González, Elena
dc.contributor.author Luque Pardos, Sònia
dc.contributor.author Fuster-Esteva, M.
dc.contributor.author Domingo, Laia
dc.contributor.author Sala Serra, Maria
dc.contributor.author Duran Jordà, Xavier, 1974-
dc.contributor.author Grau Cerrato, Santiago
dc.contributor.author Ferrández, Olivia
dc.date.accessioned 2023-04-05T06:15:51Z
dc.date.available 2023-04-05T06:15:51Z
dc.date.issued 2022
dc.identifier.citation Barceló-Vidal J, Echeverría-Esnal D, Carballo N, De Antonio-Cuscó M, Fernández-Sala X, Navarrete-Rouco ME, Colominas-González E, Luque S, Fuster-Esteva M, Domingo L, Sala M, Duran X, Grau S, Ferrández O. Drug-related problems in patients admitted for SARS-CoV-2 infection during the COVID-19 pandemic. Front Pharmacol. 2022 Nov 24;13:993158. DOI: 10.3389/fphar.2022.993158
dc.identifier.issn 1663-9812
dc.identifier.uri http://hdl.handle.net/10230/56409
dc.description.abstract Introduction: Drug-related problems (DRP) are events or circumstances in which drug therapy does or could interfere with desired health outcomes. In December 2019, a new coronavirus, SARS-CoV-2, appeared. Little knowledge about this type of infection resulted in the administration of various drugs with limited use in other pathologies. Evidence about DRP in patients with COVID-19 is lacking. Objective: The aim of the present study is to describe identified cases of DRP and those drugs involved in the first wave of patients with COVID-19, and evaluate associated risk factors. Material and methods: Observational, retrospective study performed in a tertiary university hospital between 14th March 2020 and 31 May 2020 (corresponding to the first COVID-19 wave). We recruited patients admitted during the study period. Exclusion criteria included age < 18 years; admission to critically ill units; and care received either in the emergency room, at-home hospitalization or a healthcare center. Results: A total of 817 patients were included. The mean age was 62.5 years (SD 16.4) (range 18-97), and 453 (55.4%) were male. A total of 516 DRP were detected. Among the patients, 271 (33.2%) presented at least one DRP. The mean DRP per patient with an identified case was 1.9. The prevailing DRPs among those observed were: incorrect dosage (over or underdosage) in 145 patients (28.2%); wrong drug combination in 131 (25.5%); prescriptions not in adherence to the then COVID-19 treatment protocol in 73 (14.1%); prescription errors due to the wrong use of the computerized physician order entry in 47 (9.2%); and incorrect dosage due to renal function in 36 (7%). The logistic regression analysis showed that patients who received only prescriptions of antibacterials for systemic use (J01 ATC group) faced a higher likelihood of experiencing a DRP (OR 2.408 (1.071-5.411), p = 0.033). Conclusion: We identified several factors associated with an increased risk of DRPs, similar to those reported in other pre-pandemic studies, including a prolonged length of stay, higher number of prescribed drugs and antimicrobial administration. The relevance of pharmacists and tools like pharmacy warning systems can help prevent, identify and resolve DRP efficiently.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Frontiers
dc.relation.ispartof Front Pharmacol. 2022 Nov 24;13:993158
dc.rights © 2022 Barceló-Vidal, Echeverría-Esnal, Carballo, De Antonio-Cuscó, Fernández-Sala, Navarrete-Rouco, Colominas-González, Luque, Fuster-Esteva, Domingo, Sala, Duran, Grau and Ferrández. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title Drug-related problems in patients admitted for SARS-CoV-2 infection during the COVID-19 pandemic
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.3389/fphar.2022.993158
dc.subject.keyword COVID-19
dc.subject.keyword SARS-CoV-2
dc.subject.keyword Antiinfective agents
dc.subject.keyword Drug medication safety
dc.subject.keyword Drug-related problem (DRP)
dc.subject.keyword Medication error
dc.subject.keyword Medication related problem
dc.subject.keyword Pharmaceutical care
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking